Uric acid and hypertension
1Department of Clinical Pharmacology, National Heart and Lung Institute, Imperial College School of Medicine, St Mary's Hospital, London, UK. M.Schachter@imperial.ac.uk
Insights
High uric acid levels link to cardiovascular disease and metabolic syndrome, potentially predicting outcomes. Further research is needed to confirm if lowering uric acid benefits hypertension management.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Nephrology
Background:
- Elevated uric acid is linked to cardiovascular disease and metabolic syndrome.
- Hyperuricemia may predict clinical outcomes and hypertension onset.
- Uric acid's role as an independent risk factor requires further clarification due to its association with other factors.
Purpose of the Study:
- To explore the association between uric acid levels and cardiovascular disease and metabolic syndrome.
- To investigate the potential role of uric acid in the pathogenesis of hypertension.
- To examine the therapeutic implications of targeting uric acid in cardiovascular and hypertensive conditions.
Main Methods:
- Review of existing literature on uric acid, cardiovascular disease, metabolic syndrome, and hypertension.
- Analysis of pathophysiological mechanisms linking uric acid to renal and vascular damage.
- Exploration of data regarding the impact of lowering uric acid on blood pressure.
Main Results:
- Increased uric acid is associated with cardiovascular disease, metabolic syndrome, and hypertension.
- Uric acid may contribute to renal and vascular damage, including endothelial dysfunction.
- Limited evidence suggests lowering uric acid might reduce blood pressure in some cases.
Conclusions:
- The precise role of uric acid as an independent risk factor for cardiovascular disease and hypertension remains under investigation.
- The relationship between elevated uric acid and triglyceride levels in metabolic syndrome needs further definition.
- Further research is required to determine if uric acid should be a therapeutic target and to establish optimal methods for lowering serum urate levels.
Abstract:
Increased levels of uric acid are associated with cardiovascular disease and the metabolic syndrome. They may predict clinical outcomes and also the onset of hypertension, though it is less clear that hyperuricaemia can be regarded as an independent risk factor given its clustering with other well-recognised factors. Uric acid may increase as a result of pathophysiological processes such as impaired renal sodium handling but may also contribute to renal and vascular damage, particularly endothelial dysfunction. It is notable that the synthesis of uric acid may be associated with the generation of reactive oxygen species if the enzyme xanthine oxidorectase is converted to the oxidase, as may occur in ischaemia. It has been suggested that uric acid may play a role in the pathogenesis of early-onset hypertension but evidence for this is limited. There is also very limited data to suggest that in some circumstances lowering uric acid can lower blood pressure. In the metabolic syndrome, the presence of elevated uric acid concentrations is closely associated with raised triglyceride levels, for reasons that have not been clearly defined. It remains to be seen whether uric acid could or should be considered a specific therapeutic target in cardiovascular disease and especially in hypertension and if so what should be the optimal pharmacological approach to lowering serum urate levels.
Related Concept Videos
Antihypertensive Drugs: Action of Diuretics
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Hypertension and Regulation of Blood Pressure
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Urinary Tract Calculi III: Medical Management
![Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F61682.jpg&w=3840&q=50)